市場調査レポート
商品コード
1180055

慢性閉塞性肺疾患治療薬の世界市場 2023-2027

Global Chronic Obstructive Pulmonary Disease Drugs Market 2023-2027

出版日: | 発行: TechNavio | ページ情報: 英文 162 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
慢性閉塞性肺疾患治療薬の世界市場 2023-2027
出版日: 2022年12月28日
発行: TechNavio
ページ情報: 英文 162 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

テクナビオは慢性閉塞性肺疾患治療薬の市場規模は、2022年から2027年の間に66億5,449万米ドル、予測期間中のCAGRは6.09%で成長すると予測しています。

当レポートでは、慢性閉塞性肺疾患治療薬市場について、全体的な分析、市場規模と予測、動向、成長促進要因、課題、さらに約25社のベンダーを網羅したベンダー分析を行っています。

現在の市場動向と促進要因、市場環境全体に関する最新の分析を提供しています。COPDの有病率の上昇、強力なパイプラインと新薬の承認、合剤に対する需要の高まりが市場を牽引しています。

本調査では、今後数年間の慢性閉塞性肺疾患治療薬市場の成長を牽引する主要な理由の一つとして、治癒的アプローチにおける研究の拡大を挙げています。また、ドラッグデリバリーデバイスの進歩や、禁煙のための電子タバコなどの利用が拡大していることも、市場の大きな需要につながると考えられます。

目次

第1章 エグゼクティブサマリー

  • 市場概要

第2章 市場情勢

  • 市場エコシステム

第3章 市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模 2022
  • 市場の見通し:2022-2027年の予測

第4章 市場規模実績

  • 世界の慢性閉塞性肺疾患治療薬市場2017年-2021年
  • 製品セグメント分析2017-2021
  • 流通チャネルセグメント分析2017-2021
  • 地域セグメント分析2017-2021
  • 国セグメント分析2017-2021

第5章 ファイブフォース分析

  • ファイブフォースの要約
  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争の脅威
  • 市況

第6章 製品別の市場セグメンテーション

  • マーケット・セグメント
  • 製品別比較
  • 併用療法 - 市場規模と予測 2022-2027
  • 単剤療法 - 市場規模と予測 2022-2027
  • 製品別の市場機会

第7章 流通チャネル別市場セグメンテーション

  • マーケット・セグメント
  • 流通チャネル別比較
  • 病院薬局 - 市場規模と予測 2022-2027
  • 小売薬局 - 市場規模と予測 2022-2027
  • オンライン薬局 - 市場規模と予測 2022-2027
  • 流通チャネル別の市場機会

第8章 顧客情勢

  • 顧客情勢の概要

第9章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較
  • 北米 - 市場規模と予測 2022-2027
  • 欧州 - 市場規模と予測 2022-2027
  • アジア - 市場規模と予測 2022-2027
  • その他の地域(ROW) - 市場規模と予測 2022-2027
  • 米国 - 市場規模と予測 2022-2027
  • 英国 - 市場規模と予測 2022-2027
  • カナダ - 市場規模と予測 2022-2027
  • ドイツ - 市場規模と予測 2022-2027
  • 日本 - 市場規模と予測 2022-2027
  • 地域情勢別の市場機会

第10章 促進要因、課題、および動向

  • 市場促進要因
  • 市場の課題
  • 促進要因と課題の影響
  • 市場動向

第11章 ベンダー情勢

  • 概要
  • ベンダー情勢
  • 混乱の状況
  • 業界のリスク

第12章 ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Cadila Pharmaceuticals Ltd.
  • Cipla Ltd.
  • Exela Pharma Sciences LLC
  • GlaxoSmithKline Plc
  • Lupin Ltd.
  • Merck and Co. Inc.
  • Mundipharma International Ltd.
  • Novartis AG
  • Shionogi and Co. Ltd.
  • Sumitomo Pharma Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma Inc.
  • Viatris Inc.

第13章 付録

図表

Exhibits:

  • Exhibits1: Executive Summary - Chart on Market Overview
  • Exhibits2: Executive Summary - Data Table on Market Overview
  • Exhibits3: Executive Summary - Chart on Global Market Characteristics
  • Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibits5: Executive Summary - Chart on Market Segmentation by Product
  • Exhibits6: Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Exhibits7: Executive Summary - Chart on Incremental Growth
  • Exhibits8: Executive Summary - Data Table on Incremental Growth
  • Exhibits9: Executive Summary - Chart on Vendor Market Positioning
  • Exhibits10: Parent market
  • Exhibits11: Market Characteristics
  • Exhibits12: Offerings of vendors included in the market definition
  • Exhibits13: Market segments
  • Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibits18: Historic Market Size - Data Table on Global chronic obstructive pulmonary disease drugs market 2017 - 2021 ($ million)
  • Exhibits19: Historic Market Size - Product Segment 2017 - 2021 ($ million)
  • Exhibits20: Historic Market Size - Distribution channel Segment 2017 - 2021 ($ million)
  • Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
  • Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
  • Exhibits23: Five forces analysis - Comparison between 2022 and 2027
  • Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
  • Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
  • Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027
  • Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027
  • Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027
  • Exhibits29: Chart on Market condition - Five forces 2022 and 2027
  • Exhibits30: Chart on Product - Market share 2022-2027 (%)
  • Exhibits31: Data Table on Product - Market share 2022-2027 (%)
  • Exhibits32: Chart on Comparison by Product
  • Exhibits33: Data Table on Comparison by Product
  • Exhibits34: Chart on Combination therapy - Market size and forecast 2022-2027 ($ million)
  • Exhibits35: Data Table on Combination therapy - Market size and forecast 2022-2027 ($ million)
  • Exhibits36: Chart on Combination therapy - Year-over-year growth 2022-2027 (%)
  • Exhibits37: Data Table on Combination therapy - Year-over-year growth 2022-2027 (%)
  • Exhibits38: Chart on Monotherapy - Market size and forecast 2022-2027 ($ million)
  • Exhibits39: Data Table on Monotherapy - Market size and forecast 2022-2027 ($ million)
  • Exhibits40: Chart on Monotherapy - Year-over-year growth 2022-2027 (%)
  • Exhibits41: Data Table on Monotherapy - Year-over-year growth 2022-2027 (%)
  • Exhibits42: Market opportunity by Product ($ million)
  • Exhibits43: Chart on Distribution Channel - Market share 2022-2027 (%)
  • Exhibits44: Data Table on Distribution Channel - Market share 2022-2027 (%)
  • Exhibits45: Chart on Comparison by Distribution Channel
  • Exhibits46: Data Table on Comparison by Distribution Channel
  • Exhibits47: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
  • Exhibits48: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
  • Exhibits49: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
  • Exhibits50: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
  • Exhibits51: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
  • Exhibits52: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
  • Exhibits53: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
  • Exhibits54: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)
  • Exhibits55: Chart on Online pharmacies - Market size and forecast 2022-2027 ($ million)
  • Exhibits56: Data Table on Online pharmacies - Market size and forecast 2022-2027 ($ million)
  • Exhibits57: Chart on Online pharmacies - Year-over-year growth 2022-2027 (%)
  • Exhibits58: Data Table on Online pharmacies - Year-over-year growth 2022-2027 (%)
  • Exhibits59: Market opportunity by Distribution Channel ($ million)
  • Exhibits60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Exhibits61: Chart on Market share By Geographical Landscape 2022-2027 (%)
  • Exhibits62: Data Table on Market share By Geographical Landscape 2022-2027 (%)
  • Exhibits63: Chart on Geographic comparison
  • Exhibits64: Data Table on Geographic comparison
  • Exhibits65: Chart on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibits66: Data Table on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibits67: Chart on North America - Year-over-year growth 2022-2027 (%)
  • Exhibits68: Data Table on North America - Year-over-year growth 2022-2027 (%)
  • Exhibits69: Chart on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibits70: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibits71: Chart on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibits72: Data Table on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibits73: Chart on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibits74: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibits75: Chart on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibits76: Data Table on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibits77: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibits78: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibits79: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibits80: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibits81: Chart on US - Market size and forecast 2022-2027 ($ million)
  • Exhibits82: Data Table on US - Market size and forecast 2022-2027 ($ million)
  • Exhibits83: Chart on US - Year-over-year growth 2022-2027 (%)
  • Exhibits84: Data Table on US - Year-over-year growth 2022-2027 (%)
  • Exhibits85: Chart on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibits86: Data Table on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibits87: Chart on UK - Year-over-year growth 2022-2027 (%)
  • Exhibits88: Data Table on UK - Year-over-year growth 2022-2027 (%)
  • Exhibits89: Chart on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibits90: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibits91: Chart on Canada - Year-over-year growth 2022-2027 (%)
  • Exhibits92: Data Table on Canada - Year-over-year growth 2022-2027 (%)
  • Exhibits93: Chart on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibits94: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibits95: Chart on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibits96: Data Table on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibits97: Chart on Japan - Market size and forecast 2022-2027 ($ million)
  • Exhibits98: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
  • Exhibits99: Chart on Japan - Year-over-year growth 2022-2027 (%)
  • Exhibits100: Data Table on Japan - Year-over-year growth 2022-2027 (%)
  • Exhibits101: Market opportunity By Geographical Landscape ($ million)
  • Exhibits102: Impact of drivers and challenges in 2022 and 2027
  • Exhibits103: Overview on Criticality of inputs and Factors of differentiation
  • Exhibits104: Overview on factors of disruption
  • Exhibits105: Impact of key risks on business
  • Exhibits106: Vendors covered
  • Exhibits107: Matrix on vendor position and classification
  • Exhibits108: AstraZeneca Plc - Overview
  • Exhibits109: AstraZeneca Plc - Product / Service
  • Exhibits110: AstraZeneca Plc - Key news
  • Exhibits111: AstraZeneca Plc - Key offerings
  • Exhibits112: Boehringer Ingelheim International GmbH - Overview
  • Exhibits113: Boehringer Ingelheim International GmbH - Business segments
  • Exhibits114: Boehringer Ingelheim International GmbH - Key news
  • Exhibits115: Boehringer Ingelheim International GmbH - Key offerings
  • Exhibits116: Boehringer Ingelheim International GmbH - Segment focus
  • Exhibits117: Cadila Pharmaceuticals Ltd. - Overview
  • Exhibits118: Cadila Pharmaceuticals Ltd. - Product / Service
  • Exhibits119: Cadila Pharmaceuticals Ltd. - Key offerings
  • Exhibits120: Cipla Ltd. - Overview
  • Exhibits121: Cipla Ltd. - Business segments
  • Exhibits122: Cipla Ltd. - Key news
  • Exhibits123: Cipla Ltd. - Key offerings
  • Exhibits124: Cipla Ltd. - Segment focus
  • Exhibits125: Exela Pharma Sciences LLC - Overview
  • Exhibits126: Exela Pharma Sciences LLC - Product / Service
  • Exhibits127: Exela Pharma Sciences LLC - Key offerings
  • Exhibits128: GlaxoSmithKline Plc - Overview
  • Exhibits129: GlaxoSmithKline Plc - Business segments
  • Exhibits130: GlaxoSmithKline Plc - Key offerings
  • Exhibits131: GlaxoSmithKline Plc - Segment focus
  • Exhibits132: Lupin Ltd. - Overview
  • Exhibits133: Lupin Ltd. - Product / Service
  • Exhibits134: Lupin Ltd. - Key news
  • Exhibits135: Lupin Ltd. - Key offerings
  • Exhibits136: Merck and Co. Inc. - Overview
  • Exhibits137: Merck and Co. Inc. - Business segments
  • Exhibits138: Merck and Co. Inc. - Key news
  • Exhibits139: Merck and Co. Inc. - Key offerings
  • Exhibits140: Merck and Co. Inc. - Segment focus
  • Exhibits141: Mundipharma International Ltd. - Overview
  • Exhibits142: Mundipharma International Ltd. - Product / Service
  • Exhibits143: Mundipharma International Ltd. - Key offerings
  • Exhibits144: Novartis AG - Overview
  • Exhibits145: Novartis AG - Business segments
  • Exhibits146: Novartis AG - Key offerings
  • Exhibits147: Novartis AG - Segment focus
  • Exhibits148: Shionogi and Co. Ltd. - Overview
  • Exhibits149: Shionogi and Co. Ltd. - Product / Service
  • Exhibits150: Shionogi and Co. Ltd. - Key offerings
  • Exhibits151: Sumitomo Pharma Co. Ltd. - Overview
  • Exhibits152: Sumitomo Pharma Co. Ltd. - Business segments
  • Exhibits153: Sumitomo Pharma Co. Ltd. - Key offerings
  • Exhibits154: Sumitomo Pharma Co. Ltd. - Segment focus
  • Exhibits155: Teva Pharmaceutical Industries Ltd. - Overview
  • Exhibits156: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibits157: Teva Pharmaceutical Industries Ltd. - Key news
  • Exhibits158: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibits159: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibits160: Theravance Biopharma Inc. - Overview
  • Exhibits161: Theravance Biopharma Inc. - Product / Service
  • Exhibits162: Theravance Biopharma Inc. - Key offerings
  • Exhibits163: Viatris Inc. - Overview
  • Exhibits164: Viatris Inc. - Business segments
  • Exhibits165: Viatris Inc. - Key offerings
  • Exhibits166: Viatris Inc. - Segment focus
  • Exhibits167: Inclusions checklist
  • Exhibits168: Exclusions checklist
  • Exhibits169: Currency conversion rates for US$
  • Exhibits170: Research methodology
  • Exhibits171: Validation techniques employed for market sizing
  • Exhibits172: Information sources
  • Exhibits173: List of abbreviations
目次
Product Code: IRTNTR70733

Technavio has been monitoring the chronic obstructive pulmonary disease drugs market and is forecast to grow by $6654.49 mn during 2022-2027, accelerating at a CAGR of 6.09% during the forecast period. Our report on the chronic obstructive pulmonary disease drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the rising prevalence of COPD, strong pipeline and new drug approvals, and growing demand for fixed-dose combinations.

Technavio's chronic obstructive pulmonary disease drugs market is segmented as below:

By Product

  • Combination therapy
  • Monotherapy

By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the expanding research in curative approaches as one of the prime reasons driving the chronic obstructive pulmonary disease drugs market growth during the next few years. Also, advances in drug delivery devices and the growing use of e-cigarettes and other products for people to quit smoking will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the chronic obstructive pulmonary disease drugs market covers the following areas:

  • Chronic obstructive pulmonary disease drugs market sizing
  • Chronic obstructive pulmonary disease drugs market forecast
  • Chronic obstructive pulmonary disease drugs market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chronic obstructive pulmonary disease drugs market vendors that include AstraZeneca Plc, Exela Pharma Sciences LLC, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Innoviva Inc., Lupin Ltd., Merck and Co. Inc., Mundipharma International Ltd., Novartis AG, Theravance Biopharma Inc., Vertex Pharmaceuticals Inc., Viatris Inc., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., CHIESI Farmaceutici SpA, Cipla Ltd., Philip Morris International Inc., Shionogi and Co. Ltd., Sumitomo Pharma Co. Ltd., and Teva Pharmaceutical Industries Ltd. Also, the chronic obstructive pulmonary disease drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
  • Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Exhibit 07: Executive Summary - Chart on Incremental Growth
  • Exhibit 08: Executive Summary - Data Table on Incremental Growth
  • Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 10: Parent market
  • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
  • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 13: Market segments
  • 3.3 Market size 2022
  • 3.4 Market outlook: Forecast for 2022-2027
  • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

  • 4.1 Global chronic obstructive pulmonary disease drugs market 2017 - 2021
  • Exhibit 18: Historic Market Size - Data Table on Global chronic obstructive pulmonary disease drugs market 2017 - 2021 ($ million)
  • 4.2 Product Segment Analysis 2017 - 2021
  • Exhibit 19: Historic Market Size - Product Segment 2017 - 2021 ($ million)
  • 4.3 Distribution channel Segment Analysis 2017 - 2021
  • Exhibit 20: Historic Market Size - Distribution channel Segment 2017 - 2021 ($ million)
  • 4.4 Geography Segment Analysis 2017 - 2021
  • Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
  • 4.5 Country Segment Analysis 2017 - 2021
  • Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

  • 5.1 Five forces summary
  • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
  • 5.2 Bargaining power of buyers
  • Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
  • 5.3 Bargaining power of suppliers
  • Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
  • 5.4 Threat of new entrants
  • Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
  • 5.5 Threat of substitutes
  • Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
  • 5.6 Threat of rivalry
  • Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
  • 5.7 Market condition
  • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Product

  • 6.1 Market segments
  • Exhibit 30: Chart on Product - Market share 2022-2027 (%)
  • Exhibit 31: Data Table on Product - Market share 2022-2027 (%)
  • 6.2 Comparison by Product
  • Exhibit 32: Chart on Comparison by Product
  • Exhibit 33: Data Table on Comparison by Product
  • 6.3 Combination therapy - Market size and forecast 2022-2027
  • Exhibit 34: Chart on Combination therapy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 35: Data Table on Combination therapy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 36: Chart on Combination therapy - Year-over-year growth 2022-2027 (%)
  • Exhibit 37: Data Table on Combination therapy - Year-over-year growth 2022-2027 (%)
  • 6.4 Monotherapy - Market size and forecast 2022-2027
  • Exhibit 38: Chart on Monotherapy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 39: Data Table on Monotherapy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 40: Chart on Monotherapy - Year-over-year growth 2022-2027 (%)
  • Exhibit 41: Data Table on Monotherapy - Year-over-year growth 2022-2027 (%)
  • 6.5 Market opportunity by Product
  • Exhibit 42: Market opportunity by Product ($ million)

7 Market Segmentation by Distribution Channel

  • 7.1 Market segments
  • Exhibit 43: Chart on Distribution Channel - Market share 2022-2027 (%)
  • Exhibit 44: Data Table on Distribution Channel - Market share 2022-2027 (%)
  • 7.2 Comparison by Distribution Channel
  • Exhibit 45: Chart on Comparison by Distribution Channel
  • Exhibit 46: Data Table on Comparison by Distribution Channel
  • 7.3 Hospital pharmacies - Market size and forecast 2022-2027
  • Exhibit 47: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
  • Exhibit 48: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
  • Exhibit 49: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
  • Exhibit 50: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
  • 7.4 Retail pharmacies - Market size and forecast 2022-2027
  • Exhibit 51: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
  • Exhibit 52: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
  • Exhibit 53: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
  • Exhibit 54: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)
  • 7.5 Online pharmacies - Market size and forecast 2022-2027
  • Exhibit 55: Chart on Online pharmacies - Market size and forecast 2022-2027 ($ million)
  • Exhibit 56: Data Table on Online pharmacies - Market size and forecast 2022-2027 ($ million)
  • Exhibit 57: Chart on Online pharmacies - Year-over-year growth 2022-2027 (%)
  • Exhibit 58: Data Table on Online pharmacies - Year-over-year growth 2022-2027 (%)
  • 7.6 Market opportunity by Distribution Channel
  • Exhibit 59: Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

  • 8.1 Customer landscape overview
  • Exhibit 60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

  • 9.1 Geographic segmentation
  • Exhibit 61: Chart on Market share By Geographical Landscape 2022-2027 (%)
  • Exhibit 62: Data Table on Market share By Geographical Landscape 2022-2027 (%)
  • 9.2 Geographic comparison
  • Exhibit 63: Chart on Geographic comparison
  • Exhibit 64: Data Table on Geographic comparison
  • 9.3 North America - Market size and forecast 2022-2027
  • Exhibit 65: Chart on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 66: Data Table on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 67: Chart on North America - Year-over-year growth 2022-2027 (%)
  • Exhibit 68: Data Table on North America - Year-over-year growth 2022-2027 (%)
  • 9.4 Europe - Market size and forecast 2022-2027
  • Exhibit 69: Chart on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 70: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 71: Chart on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibit 72: Data Table on Europe - Year-over-year growth 2022-2027 (%)
  • 9.5 Asia - Market size and forecast 2022-2027
  • Exhibit 73: Chart on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 74: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 75: Chart on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibit 76: Data Table on Asia - Year-over-year growth 2022-2027 (%)
  • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
  • Exhibit 77: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 78: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 79: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibit 80: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • 9.7 US - Market size and forecast 2022-2027
  • Exhibit 81: Chart on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 82: Data Table on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 83: Chart on US - Year-over-year growth 2022-2027 (%)
  • Exhibit 84: Data Table on US - Year-over-year growth 2022-2027 (%)
  • 9.8 UK - Market size and forecast 2022-2027
  • Exhibit 85: Chart on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibit 86: Data Table on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibit 87: Chart on UK - Year-over-year growth 2022-2027 (%)
  • Exhibit 88: Data Table on UK - Year-over-year growth 2022-2027 (%)
  • 9.9 Canada - Market size and forecast 2022-2027
  • Exhibit 89: Chart on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibit 90: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibit 91: Chart on Canada - Year-over-year growth 2022-2027 (%)
  • Exhibit 92: Data Table on Canada - Year-over-year growth 2022-2027 (%)
  • 9.10 Germany - Market size and forecast 2022-2027
  • Exhibit 93: Chart on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibit 94: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibit 95: Chart on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibit 96: Data Table on Germany - Year-over-year growth 2022-2027 (%)
  • 9.11 Japan - Market size and forecast 2022-2027
  • Exhibit 97: Chart on Japan - Market size and forecast 2022-2027 ($ million)
  • Exhibit 98: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
  • Exhibit 99: Chart on Japan - Year-over-year growth 2022-2027 (%)
  • Exhibit 100: Data Table on Japan - Year-over-year growth 2022-2027 (%)
  • 9.12 Market opportunity By Geographical Landscape
  • Exhibit 101: Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers
  • 10.2 Market challenges
  • 10.3 Impact of drivers and challenges
  • Exhibit 102: Impact of drivers and challenges in 2022 and 2027
  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview
  • 11.2 Vendor landscape
  • Exhibit 103: Overview on Criticality of inputs and Factors of differentiation
  • 11.3 Landscape disruption
  • Exhibit 104: Overview on factors of disruption
  • 11.4 Industry risks
  • Exhibit 105: Impact of key risks on business

12 Vendor Analysis

  • 12.1 Vendors covered
  • Exhibit 106: Vendors covered
  • 12.2 Market positioning of vendors
  • Exhibit 107: Matrix on vendor position and classification
  • 12.3 AstraZeneca Plc
  • Exhibit 108: AstraZeneca Plc - Overview
  • Exhibit 109: AstraZeneca Plc - Product / Service
  • Exhibit 110: AstraZeneca Plc - Key news
  • Exhibit 111: AstraZeneca Plc - Key offerings
  • 12.4 Boehringer Ingelheim International GmbH
  • Exhibit 112: Boehringer Ingelheim International GmbH - Overview
  • Exhibit 113: Boehringer Ingelheim International GmbH - Business segments
  • Exhibit 114: Boehringer Ingelheim International GmbH - Key news
  • Exhibit 115: Boehringer Ingelheim International GmbH - Key offerings
  • Exhibit 116: Boehringer Ingelheim International GmbH - Segment focus
  • 12.5 Cadila Pharmaceuticals Ltd.
  • Exhibit 117: Cadila Pharmaceuticals Ltd. - Overview
  • Exhibit 118: Cadila Pharmaceuticals Ltd. - Product / Service
  • Exhibit 119: Cadila Pharmaceuticals Ltd. - Key offerings
  • 12.6 Cipla Ltd.
  • Exhibit 120: Cipla Ltd. - Overview
  • Exhibit 121: Cipla Ltd. - Business segments
  • Exhibit 122: Cipla Ltd. - Key news
  • Exhibit 123: Cipla Ltd. - Key offerings
  • Exhibit 124: Cipla Ltd. - Segment focus
  • 12.7 Exela Pharma Sciences LLC
  • Exhibit 125: Exela Pharma Sciences LLC - Overview
  • Exhibit 126: Exela Pharma Sciences LLC - Product / Service
  • Exhibit 127: Exela Pharma Sciences LLC - Key offerings
  • 12.8 GlaxoSmithKline Plc
  • Exhibit 128: GlaxoSmithKline Plc - Overview
  • Exhibit 129: GlaxoSmithKline Plc - Business segments
  • Exhibit 130: GlaxoSmithKline Plc - Key offerings
  • Exhibit 131: GlaxoSmithKline Plc - Segment focus
  • 12.9 Lupin Ltd.
  • Exhibit 132: Lupin Ltd. - Overview
  • Exhibit 133: Lupin Ltd. - Product / Service
  • Exhibit 134: Lupin Ltd. - Key news
  • Exhibit 135: Lupin Ltd. - Key offerings
  • 12.10 Merck and Co. Inc.
  • Exhibit 136: Merck and Co. Inc. - Overview
  • Exhibit 137: Merck and Co. Inc. - Business segments
  • Exhibit 138: Merck and Co. Inc. - Key news
  • Exhibit 139: Merck and Co. Inc. - Key offerings
  • Exhibit 140: Merck and Co. Inc. - Segment focus
  • 12.11 Mundipharma International Ltd.
  • Exhibit 141: Mundipharma International Ltd. - Overview
  • Exhibit 142: Mundipharma International Ltd. - Product / Service
  • Exhibit 143: Mundipharma International Ltd. - Key offerings
  • 12.12 Novartis AG
  • Exhibit 144: Novartis AG - Overview
  • Exhibit 145: Novartis AG - Business segments
  • Exhibit 146: Novartis AG - Key offerings
  • Exhibit 147: Novartis AG - Segment focus
  • 12.13 Shionogi and Co. Ltd.
  • Exhibit 148: Shionogi and Co. Ltd. - Overview
  • Exhibit 149: Shionogi and Co. Ltd. - Product / Service
  • Exhibit 150: Shionogi and Co. Ltd. - Key offerings
  • 12.14 Sumitomo Pharma Co. Ltd.
  • Exhibit 151: Sumitomo Pharma Co. Ltd. - Overview
  • Exhibit 152: Sumitomo Pharma Co. Ltd. - Business segments
  • Exhibit 153: Sumitomo Pharma Co. Ltd. - Key offerings
  • Exhibit 154: Sumitomo Pharma Co. Ltd. - Segment focus
  • 12.15 Teva Pharmaceutical Industries Ltd.
  • Exhibit 155: Teva Pharmaceutical Industries Ltd. - Overview
  • Exhibit 156: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 157: Teva Pharmaceutical Industries Ltd. - Key news
  • Exhibit 158: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 159: Teva Pharmaceutical Industries Ltd. - Segment focus
  • 12.16 Theravance Biopharma Inc.
  • Exhibit 160: Theravance Biopharma Inc. - Overview
  • Exhibit 161: Theravance Biopharma Inc. - Product / Service
  • Exhibit 162: Theravance Biopharma Inc. - Key offerings
  • 12.17 Viatris Inc.
  • Exhibit 163: Viatris Inc. - Overview
  • Exhibit 164: Viatris Inc. - Business segments
  • Exhibit 165: Viatris Inc. - Key offerings
  • Exhibit 166: Viatris Inc. - Segment focus

13 Appendix

  • 13.1 Scope of the report
  • 13.2 Inclusions and exclusions checklist
  • Exhibit 167: Inclusions checklist
  • Exhibit 168: Exclusions checklist
  • 13.3 Currency conversion rates for US$
  • Exhibit 169: Currency conversion rates for US$
  • 13.4 Research methodology
  • Exhibit 170: Research methodology
  • Exhibit 171: Validation techniques employed for market sizing
  • Exhibit 172: Information sources
  • 13.5 List of abbreviations
  • Exhibit 173: List of abbreviations